Close Menu

NEW YORK – Predictive Oncology subsidiary Helomics has signed a pair of agreements to use its artificial intelligence-based platform in oncology decision making.

First, Helomics said today that it is partnering with the University of Pittsburgh Medical Center to use AI to potentially improve clinical decision making for ovarian cancer patients. In addition, Interpace Diagnostics said that it is working with Helomics to develop tools that diagnose and assess the risk of thyroid cancer.  

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.